drugset / Trial / NCT03738397

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03738397

Phase 3 Completed 673 enrolled AbbVie
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate upadacitinib compared to dupilumab (Dupixent®) in adults with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

Timeline

Start
2019-02-21
Primary completion
2020-08-27
Completion
2020-12-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dupilumab Monoclonal antibody 300 mg Subcutaneous
Subject Upadacitinib Small molecule 30 mg Oral

Indications